Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
4,287 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02568267 | Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)(STARTRK-2) | active not recruiting | Phase 2 | 534 | Hoffmann-La RocheINDUSTRY | 16 | Aug 25, 2026 | clinicaltrials |
| NCT03604198 | Extension Study to Evaluate the Safety of Long-Term Use of Relacorilant in Patients With Cushing Syndrome | active not recruiting | Phase 2 | 125 | Corcept TherapeuticsINDUSTRY | 9 |
| Aug 25, 2026 |
| clinicaltrials |
| NCT06024772 | Multiparametric Ultrasound for the Diagnosis of Clinically Significant Prostate Cancer | not yet recruiting | Phase 3 | 300 | Thomas Jefferson UniversityOTHER | 2 | Aug 25, 2026 | clinicaltrials |
| NCT06797362 | Expanded Access Program of Zidesamtinib (NVL-520) for Patients With Advanced ROS1+ NSCLC or Other ROS1+ Solid Tumors | available | — | — | Nuvalent Inc.INDUSTRY | 10 | Aug 25, 2026 | clinicaltrials |
| NCT06923475 | Neoadjuvant Gemcitabine and Cisplatin in Combination With Perioperative Pembrolizumab Versus Upfront Surgery for Patients With Primary Resectable and Borderline Resectable Perihilar and Distal Cholangiocarcinoma(NEODISCO) | recruiting | Phase 2 / Phase 3 | 150 | Amsterdam UMC, location VUmcOTHER | 1 | Aug 25, 2026 | clinicaltrials |
| NCT07227311 | A Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Standard of Care in Participants With Relapsed-Refractory Multiple Myeloma (RRMM) | recruiting | Phase 2 | 200 | GlaxoSmithKlineINDUSTRY | 8 | Aug 25, 2026 | clinicaltrials |
| NCT00463814 | AZD6244 (ARRY-142886) Solid Oral Dosage Formulation in Participants With Advanced Solid Malignancies | active not recruiting | Phase 1 | 58 | AstraZenecaINDUSTRY | 3 | Aug 24, 2026 | clinicaltrials |
| NCT02046733 | Small Cell Lung Carcinoma Trial With Nivolumab and IpiliMUmab in LImited Disease(STIMULI) | completed | Phase 2 | 222 | ETOP IBCSG Partners FoundationNETWORK | 8 | Aug 24, 2026 | clinicaltrials |
| NCT02434081 | NIvolumab COmbination With Standard First-line Chemotherapy and Radiotherapy in Locally Advanced Stage IIIA/B Non-Small Cell Lung Carcinoma(NICOLAS) | completed | Phase 2 | 94 | ETOP IBCSG Partners FoundationNETWORK | 5 | Aug 24, 2026 | clinicaltrials |
| NCT05020236 | A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments(MAGNETISMM-5) | recruiting | Phase 3 | 893 | PfizerINDUSTRY | 26 | Aug 24, 2026 | clinicaltrials |
| NCT05183035 | Venetoclax in Children With Relapsed Acute Myeloid Leukemia (AML) | recruiting | Phase 3 | 130 | PedAL BCU, LLCOTHER | 20 | Aug 24, 2026 | clinicaltrials |
| NCT05388370 | PASS of Paediatric Patients Initiating Selumetinib | active not recruiting | — | 124 | AstraZenecaINDUSTRY | 10 | Aug 24, 2026 | clinicaltrials |
| NCT03530397 | A Study to Evaluate MEDI5752 in Subjects With Advanced Solid Tumors | active not recruiting | Phase 1 | 400 | MedImmune LLCINDUSTRY | 9 | Aug 21, 2026 | clinicaltrials |
| NCT03764553 | Liposomal iRInotecan, Carboplatin or oXaliplatin for Esophagogastric Cancer(LyRICX) | active not recruiting | Phase 2 | 320 | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)OTHER | 1 | Aug 21, 2026 | clinicaltrials |
| NCT03940703 | A Study of Tepotinib Plus Osimertinib in Osimertinib Relapsed MET Amplified NSCLC (INSIGHT 2) | completed | Phase 2 | 140 | EMD Serono Research & Development Institute, Inc.INDUSTRY | 17 | Aug 21, 2026 | clinicaltrials |
| NCT05249075 | Micro-Tech FNB Needle to Obtain Tissue Specimens of Pancreas Malignancy for Personalized Based Chemotherapy(MT-FNB) | completed | — | 138 | Radboud University Medical CenterOTHER | 1 | Aug 21, 2026 | clinicaltrials |
| NCT05963867 | A Study to Test How BI 764532 is Taken up by Tumours in People With Small-cell Lung Cancer or Neuroendocrine Cancer | recruiting | Phase 1 | 12 | Boehringer IngelheimINDUSTRY | 1 | Aug 21, 2026 | clinicaltrials |
| NCT06414954 | Safety and Efficacy of 3 Dose Levels of NMD670 in Adult Patients With Myasthenia Gravis(SYNAPSE-MG) | recruiting | Phase 2 | 84 | NMD Pharma A/SINDUSTRY | 10 | Aug 21, 2026 | clinicaltrials |
| NCT07641985 | Autologous Fat Grafting for Total Breast Reconstruction in Irradiated Breast Cancer Patients(AFT-R) | recruiting | N/A | 280 | Maastricht University Medical CenterOTHER | 1 | Aug 21, 2026 | clinicaltrials |
| NCT01792934 | Chemotherapy and Maximal Tumor Debulking of Multi-organ Colorectal Cancer Metastases(ORCHESTRA) | active not recruiting | N/A | 478 | Radboud University Medical CenterOTHER | 2 | Aug 20, 2026 | clinicaltrials |
| NCT03785964 | Nirogacestat for Adults With Desmoid Tumor/Aggressive Fibromatosis (DT/AF)(DeFi) | completed | Phase 3 | 142 | SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, GermanyINDUSTRY | 7 | Aug 20, 2026 | clinicaltrials |
| NCT04008030 | A Study of Nivolumab, Nivolumab Plus Ipilimumab, or Investigator's Choice Chemotherapy for the Treatment of Participants With Deficient Mismatch Repair (dMMR)/Microsatellite Instability High (MSI-H) Metastatic Colorectal Cancer (mCRC)(CheckMate 8HW) | active not recruiting | Phase 3 | 839 | Bristol-Myers SquibbINDUSTRY | 24 | Aug 20, 2026 | clinicaltrials |
| NCT04886804 | Beamion LUNG-1: A Study to Test Different Doses of Zongertinib in People With Different Types of Advanced Cancer (Solid Tumours With Changes in the HER2 Gene) | active not recruiting | Phase 1 | 554 | Boehringer IngelheimINDUSTRY | 18 | Aug 20, 2026 | clinicaltrials |
| NCT05157659 | [18F]F-AraG PET Imaging to Visualize Tumor Infiltrating T-cell Activation in Non-small Cell Lung Cancer.(ATTAIN) | active not recruiting | N/A | 10 | Amsterdam UMC, location VUmcOTHER | 1 | Aug 20, 2026 | clinicaltrials |
| NCT05614739 | FORAGER-1: A Study of Vepugratinib (LY3866288; LOXO-435) in Participants With Cancer With a Change in a Gene Called FGFR3(FORAGER-1) | recruiting | Phase 1 | 677 | Eli Lilly and CompanyINDUSTRY | 14 | Aug 20, 2026 | clinicaltrials |
| NCT05724602 | Radiotherapy Plus Xevinapant in Older Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma(RAVINA) | terminated | Phase 2 | 13 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 10 | Aug 20, 2026 | clinicaltrials |
| NCT06595563 | HER2 Molecular Imaging With 89Zr-trastuzumab PET/CT as a Predictive Biomarker for Antibody-drug Conjugate Sequencing in Patients With Advanced HER2-positive Breast Cancer(ZEPHIR-02) | terminated | Phase 2 | 87 | Jules Bordet InstituteOTHER | 2 | Aug 20, 2026 | clinicaltrials |
| NCT06908070 | Chemoradiotherapy With Surgery Followed by Consolidation Durvalumab(CROWD) | recruiting | Phase 4 | 38 | Idris BahceOTHER | 1 | Aug 20, 2026 | clinicaltrials |
| NCT03007147 | Imatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia | active not recruiting | Phase 3 | 352 | Children's Oncology GroupNETWORK | 19 | Aug 19, 2026 | clinicaltrials |
| NCT03876769 | Study of Efficacy and Safety of Tisagenlecleucel in HR B-ALL EOC MRD Positive Patients(CASSIOPEIA) | active not recruiting | Phase 2 | 121 | Novartis PharmaceuticalsINDUSTRY | 11 | Aug 19, 2026 | clinicaltrials |
| NCT05774951 | A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy(CAMBRIA-1) | recruiting | Phase 3 | 4,300 | AstraZenecaINDUSTRY | 39 | Aug 19, 2026 | clinicaltrials |
| NCT06467357 | Phase 3 Study of T-DXd and Rilvegostomig Versus SoC in Advanced HER2-expressing Biliary Tract Cancer(DESTINY-BTC01) | recruiting | Phase 3 | 620 | AstraZenecaINDUSTRY | 27 | Aug 19, 2026 | clinicaltrials |
| NCT07412197 | Preventive Dendritic Cell Vaccination for Lynch Syndrome(PREVENT-Lynch) | not yet recruiting | Phase 1 / Phase 2 | 16 | Radboud University Medical CenterOTHER | 1 | Aug 19, 2026 | clinicaltrials |
| NCT03106779 | Study of Efficacy of CML-CP Patients Treated With ABL001 Versus Bosutinib, Previously Treated With 2 or More TKIs | completed | Phase 3 | 233 | Novartis PharmaceuticalsINDUSTRY | 25 | Aug 18, 2026 | clinicaltrials |
| NCT03732820 | Study on Olaparib Plus Abiraterone as First-line Therapy in Men With Metastatic Castration-resistant Prostate Cancer | active not recruiting | Phase 3 | 895 | AstraZenecaINDUSTRY | 17 | Aug 18, 2026 | clinicaltrials |
| NCT04880434 | Study of Brexucabtagene Autoleucel (KTE-X19) in Participants With Relapsed/Refractory Mantle Cell Lymphoma (Cohort 3)(ZUMA-2) | completed | Phase 2 | 95 | Kite, A Gilead CompanyINDUSTRY | 6 | Aug 18, 2026 | clinicaltrials |
| NCT05701176 | A Clinical Imaging Study of the Changes in [18F]F-AraG Uptake Following Anti-PD-1 Therapy in Non-small Cell Lung Cancer(SHARP) | recruiting | N/A | 15 | Amsterdam UMC, location VUmcOTHER | 1 | Aug 18, 2026 | clinicaltrials |
| NCT06457789 | Assessment of PET Tracers to Evaluate T Cell Change and Activation in Relation to Immunotherapy Treatment Response in Non-Small Cell Lung Cancer(iRelate) | recruiting | N/A | 34 | Amsterdam UMC, location VUmcOTHER | 1 | Aug 18, 2026 | clinicaltrials |
| NCT06743126 | SUPRAME-ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma(SUPRAME) | recruiting | Phase 3 | 360 | Immatics US, Inc.INDUSTRY | 6 | Aug 18, 2026 | clinicaltrials |
| NCT06792695 | A Study of Novel Study Interventions and Combinations in Participants With Colorectal Cancer(CANTOR) | recruiting | Phase 2 | 80 | AstraZenecaINDUSTRY | 12 | Aug 18, 2026 | clinicaltrials |
| NCT07009184 | TGW211 for Click-Cleavable Imaging in HER2-Positive Cancers.(CleavHER) | recruiting | Early Phase 1 | 19 | Radboud University Medical CenterOTHER | 1 | Aug 18, 2026 | clinicaltrials |
| NCT03965468 | Immunotherapy, Chemotherapy, Radiotherapy and Surgery for Synchronous Oligo-metastatic NSCLC(CHESS) | active not recruiting | Phase 2 | 96 | ETOP IBCSG Partners FoundationNETWORK | 4 | Aug 17, 2026 | clinicaltrials |
| NCT04891289 | Gemcitabine and Oxaliplatin Chemotherapy With or Without a Floxuridine and Dexamethasone Pump in People With Cholangiocarcinoma That Cannot Be Removed With Surgery | recruiting | Phase 2 | 164 | Memorial Sloan Kettering Cancer CenterOTHER | 2 | Aug 17, 2026 | clinicaltrials |
| NCT05853575 | Trial of Two Adagrasib Dosing Regimens in NSCLC With KRAS G12C Mutation (KRYSTAL 21) | active not recruiting | Phase 2 | 200 | Mirati Therapeutics Inc.INDUSTRY | 18 | Aug 14, 2026 | clinicaltrials |
| NCT06072781 | A Study of Avutometinib (VS-6766) + Defactinib (VS-6063) in Recurrent Low-Grade Serous Ovarian Cancer(RAMP 301) | recruiting | Phase 3 | 270 | Verastem, Inc.INDUSTRY | 16 | Aug 14, 2026 | clinicaltrials |
| NCT01784068 | Nilotinib Treatment-free Remission Study in CML (Chronic Myeloid Leukemia) Patients(ENESTfreedom) | completed | Phase 2 | 215 | Novartis PharmaceuticalsINDUSTRY | 19 | Aug 13, 2026 | clinicaltrials |
| NCT03782207 | A Study Investigating the Outcomes and Safety of Atezolizumab Under Real-World Conditions in Patients Treated in Routine Clinical Practice(IMreal) | completed | — | 2,756 | Hoffmann-La RocheINDUSTRY | 30 | Aug 13, 2026 | clinicaltrials |
| NCT04603807 | A Study to Compare the Efficacy and Safety of Entrectinib and Crizotinib in Participants With Advanced or Metastatic ROS1 Non-small Cell Lung Cancer (NSCLC) With and Without Central Nervous System (CNS) Metastases | active not recruiting | Phase 3 | 217 | Hoffmann-La RocheINDUSTRY | 18 | Aug 13, 2026 | clinicaltrials |
Data updated 23 days agoSource updated unknownsource: clinicaltrials